Positron Emission Tomography in Breast Cancer

• Main Authors: Jose Luis Vercher-Conejero, Laura Pelegrí-Martinez, Diego Lopez-Aznar, María del Puig Cózar-Santiago
• Format: Article
• Language: English
• Published: MDPI AG 2015-03-01
• Series: Diagnostics
• Subjects: FDG-PET; PET/CT; PET/MRI; breast cancer; dedicated breast PET; non-FDG radiopharmaceuticals
• Online Access: http://www.mdpi.com/2075-4418/5/1/61

Gradually, FDG-PET/CT has been strengthening within the diagnostic algorithms of oncological diseases. In many of these, PET/CT has shown to be useful at different stages of the disease: diagnosis, staging or re-staging, treatment response assessment, and recurrence. Some of the advantages of this imaging modality versus CT, MRI, bone scan, mammography, or ultrasound, are based on its great diagnostic capacity since, according to the radiopharmaceutical used, it reflects metabolic changes that often occur before morphological changes and therefore allows us to stage at diagnosis. Moreover, another advantage of this technique is that it allows us to evaluate the whole body so it can be very useful for the detection of distant disease. With regard to breast cancer, FDG-PET/CT has proven to be important when recurrence is suspected or in the evaluation of treatment response. The technological advancement of PET equipment through the development of new detectors and equipment designed specifically for breast imaging, and the development of more specific radiopharmaceuticals for the study of the different biological processes of breast cancer, will allow progress not only in making the diagnosis of the disease at an early stage but also in enabling personalized therapy for patients with breast cancer.